|
|
 |
You are in: Home :: News Story |
NEWS STORY
 |
 |
 |
 |
 |
 |
 |
Kenyans Rally Against EU-India Deal on AIDs
Drugs
|
 |
Reuters
December 9, 2010
By Katy Migiro
Hundreds
of Kenyans living with HIV protested outside EU offices in Nairobi
on Thursday against a deal they say may block access to cheap
life-saving AIDS drugs.
The European Union and India are due to discuss a free-trade
agreement in Brussels on Friday which campaigners say will cause
shortages of generic antiretroviral (ARV) drugs. A U.N. study found
that the proposed deal could make generics more expensive.
Under the proposed deal, patent terms would be extended beyond 20
years while data exclusivity provisions would force Indian
manufacturers to carry out their own clinical trials instead of
using existing data.
This would delay registration of generic ARVs for several years,
according to the U.N.
"Unless the attacks by the European Commission on the future of
generic production in India are stopped, costs will rise, ARV access
will be rationed and patients will die," said Hussein Kerrow of the
advocacy group Medecins sans Frontieres.
Generic ARVs cost about $137 per person per year, a fraction of
the price of patented ARVs used to treat the human immunodeficiency
virus (HIV) that causes AIDS, and are sold by Western pharmaceutical
companies.
Only a third of the 14.6 million people around the world who need
ARVs are currently receiving them. More than 80 percent of those
using them, as well as patients in developing countries, get their
drugs from India, activists say.
"We depend on these drugs from India because they are cheap and
they are very good," said Tom Osongo, 62, a demonstrator.
The placard-waving protestors presented a petition to Eric van
der Linden, the EU's head of delegation in Kenya, who said that he
would pass on their message but gave no promises.
"I am not a magician," he said.
HIV positive Osongo said he had been suffering from tuberculosis,
pneumonia and typhoid, until six years ago, when he started on the
life-enhancing drugs.
"If they (generic ARVs) are not available, the first thing that
would happen is me to go back down with the disease and maybe even
die," he said.
story url
|
 |
|
|